NLGN4Y and prostate cancer: Among these SVs, one affected NLGN4Y (neuroligin 4, Y-linked) specifically in HepG2-2.2.15, which is a tumor suppressor in prostate cancer (37) and may contribute to the male dominance of HCC incidence.